Blue Fin Group, a management and technology consulting firm focused on the pharmaceutical, biotechnology and healthcare industries, is pleased to announce the addition of Michael Turner as Partner.
Michael is a strategic partner who brings over 20 years of experience in pharmaceutical strategy and is expected to expand Blue Fin Group’s robust portfolio of offerings, having helped a large spectrum of manufacturers design and build their portfolio and product strategies. Michael has been a trusted advisor to commercial leaders assisting in new product planning, commercial strategy development, product launch, in-line brand strategy, portfolio strategy and commercial capability design and development. He has worked across most therapeutic areas and was involved in over 50 global pharmaceutical and biopharma product launches, including partnering with many companies to help them prepare for their first commercial launch.
Most recently, he was a Partner at PA Consulting and prior to that was Managing Director at Campbell Alliance, a consulting firm focused on pharmaceutical strategy and an inVentiv Health company, where he held several leadership roles and helped to build and lead the Commercial Strategy practice. Michael’s past positions have also included Chairman of the Campbell Alliance Strategy Committee, and General Manager of Encuity Research, a syndicated market research company that he led and launched in 2011. Michael also held consulting and leadership positions at marketRx (now Cognizant) and ZS Associates.
Blue Fin Group is proud to service over 200 healthcare clients across the pharmaceutical and healthcare ecosystem. For more information about Blue Fin Group, our associates and service offerings, please visit www.consultbfg.com.